Bill Haney's Skyhawk spears another marquee alliance for its work drugging RNA in Takeda neuro pact
Bill Haney’s Skyhawk Therapeutics has scored another high-profile development partner.
Coming after its Shire buyout, Takeda has allied with Skyhawk to discover new small molecules for unspecified neurological conditions. There’s no word on terms, but Haney has had considerable success in gaining significant upfronts for his discovery deals. Skyhawk earlier tied up with a troubled Biogen, while Celgene provided $100 million in cash to determine how Skyhawk’s platform drugging RNA works.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.